Estrogen therapy helps or hurts the brain depending on reproductive statusJune 16, 2008Estrogen therapy may limit stroke damage if started close to, but not long after reproductive cycles are over, according to a new animal study. The results were presented Sunday, June 15, at The Endocrine Society's 90th Annual Meeting in San Francisco. "This study suggests that estrogen treatment is not toxic per se but that its effects on the brain depend on the individual's reproductive age when therapy begins," said one of the study's authors, Farida Sohrabji, PhD, of Texas A & M Health Science Center. In their study in rats, Amutha Selvamani, a post-doctoral associate and Dr. Sohrabji, found "that estrogen treatment is not beneficial to the brain once the animal is in an acylic state, but is effective when given earlier. This acyclic stage in animals shares similarities with the menopausal stage in women."
Since the Women's Health Initiative study found that long-term therapy with estrogen or estrogen plus progestin may increase the risk of heart attack and stroke, many women have found it difficult to decide whether to take hormone therapy at menopause. Subsequently, several researchers have speculated that the timing of estrogen treatment may be important for estrogen's effects. The authors therefore designed an animal study to determine if estrogen would be beneficial for females who are going through menopause (perimenopausal) but not for women who are postmenopausal for many years. Since it is not possible to measure "risk" in animal studies, the authors measured severity of stroke injury. Therefore, they compared groups of female rats: mature adults and older, "acyclic" rats that no longer had reproductive cycles. The physiologic status of the older rats resembled that of a postmenopausal woman, and the other rats' status would be more similar to perimenopause, according to Sohrabji. After surgically removing the ovaries of all the rats, the researchers gave them estrogen replacement therapy (estradiol) for 3 weeks. Then they induced a stroke in all the animals. A week later, the rats' brains were studied for tissue damage. The stroke caused much more tissue damage in the acyclic older females, the authors reported. "Estrogen treatment to this group actually increased the volume of the brain that was damaged," Sohrabji said. In the mature adult rats, however, estrogen therapy apparently reduced the area of brain damage. After the stroke all rats showed evidence of sensory and motor damage on behavioral testing, but it was more severe in the acyclic rats. "This study supports the idea that there is a narrow window of time as a woman approaches menopause and immediately afterward where estrogen therapy may provide neuroprotective benefits," Sohrabji said. The Endocrine Society | |||||||||||||||||||||
|
Related Estrogen Therapy News Articles Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis Cancer patients with low socioeconomic status (SES) have more advanced cancers at diagnosis, receive less aggressive treatment, and have a higher risk of dying in the five years following cancer diagnosis, according to a new study. Popular osteoporosis drugs triple risk of bone necrosis A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain. Effects of progesterone on Alzheimer's disease The first study on progesterone and Alzheimer's disease has found no clear preventive benefit for the widely prescribed hormone in an animal model. Study Suggests Estrogen Deficiency Can Lead To Obesity-Induced At menopause, women lose hormone protection against heart (cardiovascular) and kidney (renal) diseases, and are likely to become obese. Study finds estrogen therapy gives aging brain cells a boost Cyclical, long-term estrogen injections protected brain cells from age-related deterioration, according to a new study conducted at Mount Sinai School of Medicine. Postmenopausal hormone therapy and coronary disease -- the truth of the matter With each new publication of coronary artery disease (CAD) data from the Women's Health Initiative (WHI) study, the inevitable reaction is "Why on earth did the WHI investigators claim in 2002-2004 that postmenopausal hormone therapy has deleterious effects on the risk for CAD, when, from the beginning, they were aware of the importance of the age factor in this clinical scenario"". Estrogen use lowered one risk factor for heart disease among some younger postmenopausal women A follow-up study to the federally funded Women's Health Initiative should help allay one concern in a subset of women in their 50s who are considering taking estrogen to relieve hot flashes. IMS reaction to report on breast cancer incidence in 2003 in US A special report in the April 19 issue of the New England Journal of Medicine [1] brings initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology and End Result (SEER) registries, showing that the incidence of breast cancer in women in the US fell by 6.7% in 2003, and stayed at the same level in 2004. Researchers identify key gene that may be a marker of breast cancer metastasis Researchers at Fox Chase Cancer Center have identified an important gene involved in the spread of breast cancer that has developed resistance to long-term estrogen deprivation. New biomarker predicts effectiveness of breast cancer drugs University of Cincinnati (UC) researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer. More Estrogen Therapy News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||